Cure Parkinson’s and Van Andel Institute (VAI) have announced Professor Oliver Bandmann as the winner of the 2024 Tom Isaacs Award, which honours researchers who closely collaborate with the Parkinson’s community. The award was virtually presented to Professor Bandmann as part of the annual Grand Challenges in Parkinson’s Disease symposium and parallel Rallying to the…
Category: ACNR News
King’s Parkinson’s Charitable Fund launches
Twenty years ago, Professor K Ray Chaudhuri and colleagues wrote in ACNR about the often neglected non-motor symptoms of Parkinson’s which impact so much on a patient’s quality of life – symptoms such as pain, poor sleep, depression, anxiety, sexual dysfunction and autonomic problems. Two decades on, the newly launched King’s Parkinson’s Charitable Fund aims…
WFNR Franz Gerstenbrand Award 2024 Winner
Dr Christian Endisch, a physician with a neurology residency at the department of Neurology and Experimental Neurology Charité Universitätsmedizin in Berlin, Germany, is the winner of the 2024 World Federation of Neurorehabilitation (WFNR) Franz Gerstenbrand Award. Announced this month at the 13th World Congress for Neurorehabilitation in Vancouver, Canada, Dr Endisch said: “I’m delighted to…
Karger Publishers Launches its Fourth Annual Vesalius Innovation Award to Advance the Future of Science
For the fourth consecutive year, Karger Publishers is seeking top-of-the-line applicants for its Vesalius Innovation Award. The award is aimed at early-stage startups in the Health Sciences and Publishing sectors that are developing innovative technological solutions with a significant impact in their respective fields. This year marks the fourth year of the Vesalius Innovation Award,…
ACNR Podcast – celebrating 20 years of ACNR
It is a great pleasure to mark ACNR’s 20th anniversary with a new departure for the reviews section. This is our first podcast review. And what better inaugural podcast to review than the ACNR’s very own, in the form of an interview by Sri Kodali. Sri questions no less a pair than Rachael Hansford, ACNR…
Positive phase III data for Neurocrine’s Ingrezza in Huntington’s disease
Neurocrine Biosciences has recently announced that its pipeline asset, Ingrezza (valbenazine), achieved the primary endpoint of reducing the symptoms of chorea (involuntary muscle movements) associated with Huntington’s disease (HD) in the Phase III clinical trial, KINECT-HD (NCT04102579). This will propel Ingrezza into a dominant position in the HD market, due to its convenient once-daily dosing…
ACNR indexed in DOAJ (Directory of Open Access Journals)
DOAJ indexes and promotes quality, peer-reviewed open access journals from around the world. It is the most important community-driven, open access service in the world and has a reputation for advocating best practices and standards in open access. DOAJ’s basic criteria for inclusion have become the accepted way of measuring an open access journal’s adherence to standards…
Find ACNR articles in EuropePMC/PubMed
We have recently added the article Hallucinations in Parkinson’s disease to EuropePMC on behalf of authors Rimona Weil and Suzanne Reeves. Is your work supported by funders on this list? If you write about your work for ACNR, we can add your article to EuropePMC with no charges for you or your institution. Contact the…
ACNR joins Crossref
We’re delighted to announce that ACNR has joined Crossref, and will be allocating DOI’s to new articles. We have also started adding DOI’s to existing articles, but as we have been publishing for almost 20 years we have quite a lot of content to work through! If you have published an article with us in…
